A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
The same trial that sent Summit up 272% sees the stock crash 36%.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
